With clear FDA path, Clementia raises $70.2M

Days after revealing regulatory plans for its therapy for a rare bone disease, Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) raised $70.2 million in a bumped-up follow-on offering.

Clementia priced 5.3 million shares at $13.25 late Oct. 29, hours after it proposed to raise $50 million. The price is a 4% discount to the stock’s closing price of $13.80 on Oct. 29, when the company proposed the offering after market hours. Underwriters are Morgan Stanley, Leerink and Wedbush PacGrow...